Schmid John P.
SEC-identified person · CIK 1478916 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Anaptysbio, INC ANAB | Director | filed 2017 - 2026 |
| First Tracks Biotherapeutics, Inc. TRAX | Director | filed 2026 - 2026 |
| Design Therapeutics, Inc. DSGN | Director | filed 2021 - 2026 |
| Helix Acquisition Corp. III HLXC | Director | filed 2026 - 2026 |
| Helix Acquisition Corp. II HLXB | Director | filed 2024 - 2025 |
| Poseida Therapeutics, Inc. PSTX | Director | filed 2020 - 2025 |
| Xeris Biopharma Holdings, Inc. XERS | Director | filed 2021 - 2024 |
| Xeris Pharmaceuticals INC XERS | Director | filed 2018 - 2021 |
| Neos Therapeutics, Inc. NEOS | Director | filed 2015 - 2021 |
| Moonlake Immunotherapeutics MLTX | Director | filed 2020 - 2020 |
| Auspex Pharmaceuticals, Inc. ASPX | Chief Financial Officer | filed 2014 - 2015 |
| Trius Therapeutics Inc TSRX | Chief Financial Officer | filed 2010 - 2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.